"This is not the kind of structural change we want in the market so that prices go down,” notes CP3 Director Walid Gellad in a Politico piece about drug companies' recent initiatives to lower prices. Gellad describes the concessions as a mix of potential positive and negative outcomes, echoing the response of analysts who are also watching these developments.